Antiplatelet Therapy in Cardiovascular Disease

Ron Waksman, MD, FACC, is Associate Director, Division of Cardiology and Director of Experimental Angioplasty & New Technologies, Washington Hospital Center, Washington, DC. Dr. Waksman is currently the Editor-in-Chief of Cardiovascular Revascularization Medicine and sits on the editorial boards of six other internationally published journals. He has been Editor/Co-Editor of six books since 1996 and has authored 22 additional book chapters. Dr. Waksman has also authored/co-authored over 250 published manuscripts and over 200 abstracts. He is also a Clinical Professor of Medicine (Cardiology) at Georgetown University, Washington, DC, USA.

“Written by an international who's-who of experts in the field, Antiplatelet Therapy also includes an entire section covering the use of antiplatelet drugs in PCIs, including percutaneous valve repair, which makes this text particularly essential to Interventional Cardiologists.”  (Kingbook73's Medical Ebook and Video Collection, 20 August 2014)

• List of Contributors, viiiForeword, xixPreface, xxiSection I: Platelet biology and pathophysiology1 Platelet Pathophysiology and its Role in Thrombosis, 3Paul A. Gurbel and Udaya S. Tantry2 Platelet Receptors and Drug Targets: COX-1, 8Thomas Hohlfeld and Karsten Schror3 Platelet Receptors and Drug Targets: P2Y12, 14Marco Cattaneo4 Platelet Receptors and Drug Targets: GP IIb/IIIa, 21Eliano Pio Navarese and Jacek Kubica5 Platelet Receptors and Drug Targets: PAR1, Collagen, vWF, Thromboxane, and Other Novel Targets, 29Ping Zhang, Lidija Covic, and Athan Kuliopulos6 Role of Inflammation and Hypercoagulability in Thrombosis, 45Paul A. Gurbel, Nachiket Apte, and Udaya S. TantrySection II: Platelet function tests7 Light Transmission Aggregometry, 53Paul A. Gurbel, Martin Gesheff, Kevin P. Bliden, and Udaya S. Tantry8 Vasodilator-Stimulated Phosphoprotein (VASP) Assay, 58Marc Laine, Franck Paganelli, and Laurent Bonello9 VerifyNow P2Y12 and Plateletworks Assays, 65Matthew J. Price, Nicoline J. Breet, and Jurriën M. ten Berg10 Multiplate Analyzer, 82Martin Orban and Dirk Sibbing11 Shear Stress-Based Platelet Function Tests, 92Nicoline J. Breet and Jurriën M. ten Berg12 Thrombelastography and Other Novel Techniques, 102Udaya S. Tantry, Vijay A. Doraiswamy, Glenn Stokken, Marvin J. Slepian, and Paul A. GurbelSection III: Antiplatelet pharmacology13 Aspirin, 111Karsten Schrör and Thomas Hohlfeld14 Cilostazol, 117Seung-Whan Lee, Duk-Woo Park, and Seung-Jung Park15 Abciximab, 125J. Emilio Exaire and Jorge F. Saucedo16 Tirofiban, 131Marco Valgimigli, Arnoud W.J. van't Hof, and Christian Hamm17 Eptifibatide, 142Nevin C. Baker and Ron Waksman18 Ticlopidine, 150Fabiana Rollini, Francesco Franchi, Ana Muñiz-Lozano, and Dominick J. Angiolillo19 Clopidogrel, 160Andrzej Budaj20 Prasugrel, 166Christoph Varenhorst, Anna Oskarsson, and Stefan James21 Elinogrel, 173Matthew J. Chung and Sunil V. Rao22 Cangrelor, 180Francesco Franchi, Fabiana Rollini, Ana Muñiz-Lozano, and Dominick J. Angiolillo23 Ticagrelor, 193Anna Oskarsson, Christoph Varenhorst, and Stefan James24 Thrombin Receptor Antagonists, 198Flavio de Souza Brito and Pierluigi TricociSection IV: Percutaneous Coronary Intervention and Antiplatelet Therapy25 Dual Antiplatelet Therapy Prior to Percutaneous Coronary Intervention, 209Fabio Mangiacapra, Annunziata Nusca, Rosetta Melfi, and Germano di Sciascio26 Duration of Dual Antiplatelet Therapy after Drug-Eluting Stent Implantation, 220Joshua P. Loh and Ron Waksman27 Antiplatelet Therapy for Patients with Acute Coronary Syndromes, 229Michael A. Gaglia, Jr. and Ray V. Matthews28 Antiplatelet Therapy in Stable Coronary Artery Disease, 237Ana Laynez and Ron Waksman29 Antiplatelet Therapy for Patients with Peripheral Arterial Disease, 245Aung Myat, Yousif Ahmad, and Simon R. Redwood30 Bleeding Risk and Outcomes of Patients Undergoing Percutaneous Coronary Intervention Treated with Antiplatelets, 253Sa'ar Minha and Ron Waksman31 Bleeding Definitions, 259Sameer Bansilal, Deborah E. Aronson, and Roxana MehranSection V: Antiplatelet Responsiveness32 Personalizing Antiplatelet Therapy, 269Paul A. Gurbel, Young-Hoon Jeong, and Udaya S. Tantry33 Aspirin Resistance, 277Muthiah Vaduganathan and Eli I. Lev34 Clopidogrel Resistance, 285Udaya S. Tantry, Kevin P. Bliden, Talha Meeran, and Paul A. Gurbel35 Genetics of Clopidogrel Poor Response, 293Pierre Fontana and Jean-Luc Reny36 Proton Pump Inhibitors and Clopidogrel, 300Michael A. Gaglia, Jr37 Other Drug Interactions with Clopidogrel, 306Eric R. BatesIndex, 314